Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AZD4205 maintenance/consolidation therapy in peripheral T-cell lymphoma after first-line systemic treatment
CTR20213318Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of golidocitinib in peripheral T-cell lymphoma (PTCL) (2 cohorts), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Adverse events and serious adverse events. Started Mar 2022; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20213318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213318.